Mesoglycan: Clinical Evidences for Use in Vascular Diseases

Table 2

Mesoglycan in peripheral obstructive arterial disease (POAD). Clinical studies.

Author	Study design	Pathology	Patients (𝑛)	Doses/route	Results
Andreozzi [18]	Prospective	POAD in stages I-II Fontaine	10	Mesoglycan 60 mg daily; for 20 days	Mesoglycan: safe and effective in improving the wall response to vasodilator stimulus
Raso [19]	Prospective	POAD stage IIb Fontaine	36	Mesoglycan 60 mg daily endovenous for 10 days then 100 mg daily orally for 20 days, repeated for two months then oral mesoglycan for 12 months	Mesoglycan: significant improvement of symptoms and signs in all patients but one
Nenci [20]	Randomized, double-blinded	PAOD stage II Fontaine	242	Mesoglycan 30 mg daily i.m. for 3 weeks then 100 mg daily orally for two weeks, versus matching placebo All patients receive ASA	Mesoglycan: significant clinical improvement versus placebo. Significant improvement in quality of life scores.